USPTO Trademark Application: KADDY+ Disc Golf App

The USPTO has received an intent-to-use trademark application for 'KADDY+' for a downloadable mobile application related to disc golf. The application covers software for scoring, performance tracking, course mapping, and gameplay management.

5O. COM Trademark Application Published for Opposition

The USPTO has published the trademark application for '5O. COM' for opposition. The application, filed on March 22, 2026, covers a range of computing and electronics goods, including antennas, amplifiers, integrated circuits, and transceivers. This publication opens a period for third parties to oppose the registration.

USPTO Trademark Application for Primepet Looks AI Image Software

The USPTO has received an intent-to-use trademark application from Primepet Looks for AI image software. The application covers SaaS and downloadable software for generating, editing, and enhancing digital images, particularly of pets, using artificial intelligence.

USPTO Trademark Application Published for Opposition

The USPTO has published a trademark application for opposition concerning downloadable software for tracking travel and visa compliance in the Schengen Area. The application was published on March 23, 2026, with a filing date of March 22, 2026.

DAYSTEPS SAAS Trademark Application

The USPTO has received an intent-to-use trademark application from DAYSTEPS for SAAS services and downloadable software. The application covers software designed to assist individuals, including those with ADHD, autism, and executive function challenges, in managing daily routines and facilitating care coordination.

XINFORG trademark application published for opposition

XINFORG trademark application published for opposition

USPTO Patent Grant for LRP6 Protein Binding Antibodies

The USPTO has granted a patent (US12583919B2) to Antlera Therapeutics Inc. for antibodies that specifically bind to LRP6 proteins and methods of their use. The patent was filed on August 14, 2020, and is set to be granted on March 24, 2026.

USPTO Patent US12583917B2: IL17A Antibodies for Veterinary Use

The USPTO has granted patent US12583917B2 to Elanco US Inc. for IL17A antibodies and antagonists intended for treating conditions in animals, including companion animals. The patent details specific antibody embodiments and IgG Fc variant polypeptides designed to reduce immune responses.

USPTO Patent Grant for Cancer Diagnosis using Anti-BAG2 Antibody

The USPTO has granted a patent (US12583915B2) to Medpacto, Inc. for methods of diagnosing cancer using an anti-BAG2 antibody. The patent covers compositions comprising antibodies that specifically bind to BAG2 polypeptides or fragments thereof.

USPTO Patent Grant: Antibody Inhibitors for Staphylococcus Aureus Treatment

The USPTO has granted patent US12583913B2 for antibody inhibitors targeting Staphylococcus aureus, specifically coagulases SC and vWbp. This patent covers therapeutic methods and detection techniques utilizing these monoclonal antibodies.